AXSM Axsome Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—
Margins
Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%
Returns
ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x
Leverage & solvency
Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $638.50M | $385.69M | $270.60M | $50.04M | — |
| Cost of revenue | $47.48M | $33.30M | $26.07M | $5.20M | — |
| Gross profit | $591.02M | $352.39M | $244.53M | $44.84M | — |
| R&D expense | $183.28M | $187.08M | $97.94M | $57.95M | $58.06M |
| SG&A expense | $570.60M | $411.36M | $323.12M | $159.25M | $66.65M |
| Operating income | -$166.76M | -$280.56M | -$231.82M | -$179.80M | -$124.71M |
| Interest expense | -$15.93M | -$21.58M | -$20.03M | -$9.66M | — |
| Pretax income | -$183.70M | -$287.13M | -$238.28M | -$187.13M | -$130.40M |
| Income tax | -$530,000 | $85,000 | $960,000 | $0 | $0 |
| Net income | -$183.17M | -$287.22M | -$239.24M | -$187.13M | -$130.40M |
| EBITDA | -$166.26M | -$280.03M | -$231.37M | -$179.54M | -$124.63M |
| EPS (basic) | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
| EPS (diluted) | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
| Weighted avg. shares (diluted) | 49.75M | 47.91M | 45.43M | 40.66M | 37.62M |
| Balance sheet | |||||
| Cash & equivalents | $322.93M | $315.35M | $386.19M | $200.84M | $86.47M |
| Receivables | $224.46M | $142.00M | $94.82M | $37.70M | — |
| Inventory | $27.94M | $15.73M | $15.13M | $4.32M | — |
| Current assets | $588.99M | $485.06M | $504.26M | $245.64M | $86.52M |
| PP&E, net | $562,000 | $584,000 | $846,000 | $722,000 | $283,846 |
| Goodwill | $12.04M | $12.04M | $12.04M | $10.31M | — |
| Intangibles | $40.52M | $46.89M | $53.29M | $59.66M | — |
| Total assets | $689.80M | $568.50M | $588.24M | $331.48M | $87.79M |
| Current liabilities | $378.84M | $230.10M | $138.85M | $96.56M | $23.07M |
| Short-term debt | $70.00M | $0 | — | — | — |
| Long-term debt | $117.75M | $180.71M | $178.07M | $94.26M | $49.09M |
| Total debt | $187.75M | $180.71M | $178.07M | $94.26M | $49.09M |
| Total liabilities | $601.51M | $511.48M | $397.26M | $221.92M | $72.15M |
| Shareholders' equity | $88.30M | $57.02M | $190.98M | $109.56M | $15.63M |
| Net debt | -$135.19M | -$134.64M | -$208.12M | -$106.58M | -$37.38M |
| Shares outstanding | 50.88M | 48.67M | 47.35M | 43.50M | 37.82M |
| Cash flow statement | |||||
| Operating cash flow | -$93.41M | -$128.41M | -$145.08M | -$116.51M | -$108.23M |
| Capital expenditure | $480,000 | $270,000 | $582,000 | $702,000 | $308,000 |
| Free cash flow | -$93.89M | -$128.68M | -$145.66M | -$117.21M | -$108.53M |
| Investing cash flow | -$480,000 | -$270,000 | -$582,000 | -$53.70M | -$308,000 |
| Financing cash flow | $101.47M | $57.84M | $331.01M | $284.58M | $11.13M |
| Depreciation & amortization | $503,000 | $532,000 | $459,000 | $263,000 | $76,000 |
| Stock-based compensation | $93.75M | $85.22M | $62.62M | $37.73M | $20.80M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.